MktsMarkets

Denali Therapeutics Inc.
NASDAQ: DNLIKey statistics
DNLI News
Stories mentioning DNLI from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | |||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | 103,846 | 97,905 | 101,950 | 102,696 | 116,227 | 99,787 | 98,238 | 91,399 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 137,357 | 137,365 | 137,434 | 134,963 | 145,580 | 129,846 | 123,187 | 116,593 |
| Operating Income (Loss) | (137,357) | (137,365) | (137,434) | (134,963) | (145,580) | (129,846) | (123,187) | (116,593) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (128,447) | (128,549) | (126,902) | (124,119) | (132,970) | (114,753) | (107,192) | (99,026) |
| Earnings Per Share (Basic) | (0.69) | (0.74) | (0.74) | (0.72) | (0.78) | (0.70) | (0.63) | (0.59) |
| Earnings Per Share (Diluted) | (0.69) | (0.74) | (0.74) | (0.72) | (0.78) | (0.70) | (0.63) | (0.59) |
| Weighted Average Shares Outstanding (Basic) | 186,637 | 172,649 | 172,421 | 171,450 | 171,222 | 164,474 | 169,457 | 168,831 |
| Weighted Average Shares Outstanding (Diluted) | 186,637 | 172,649 | 172,421 | 171,450 | 171,222 | 164,474 | 169,457 | 168,831 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About DNLI
Denali Therapeutics Inc. (NASDAQ: DNLI) is a stock listed on the Nasdaq Stock Market under the ticker symbol DNLI. It last traded at $19.39 (Nov 12, 2026, 9:30 AM ET), down 1.7% on the day. That gives Denali Therapeutics a market capitalisation of $2.9B.
Over the past 52 weeks DNLI has traded between $15.34 and $27.30.
For the quarter ended Mar 31, 2026 it reported a net loss of $128.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$128.4M |
| Dec 31, 2025 | — | -$128.5M |
| Sep 30, 2025 | — | -$126.9M |
| Jun 30, 2025 | — | -$124.1M |
From Denali Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…